Kadokura T - Search Results

1

A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.

Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, Cheong JW, Ikezoe T, Naoe T, Akashi K, Morita S, Kosako M, Ikegaya M, Terada W, Kadokura T, Hill J, Miyawaki S, Gill SC, Heinloth A, Hasabou N. Sawa M, et al. Among authors: kadokura t. Int J Hematol. 2024 Nov 6. doi: 10.1007/s12185-024-03840-x. Online ahead of print. Int J Hematol. 2024. PMID: 39503987

2

Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

Wang J, Jiang B, Li J, Liu L, Du X, Jiang H, Hu J, Yuan M, Sakatani T, Kadokura T, Takeuchi M, Kosako M, Ma X, Girshova L, Tan J, Bondarenko S, Lee LWL, Khuhapinant A, Martynova E, Hasabou N. Wang J, et al. Among authors: kadokura t. Leukemia. 2024 Nov;38(11):2410-2418. doi: 10.1038/s41375-024-02382-9. Epub 2024 Sep 5. Leukemia. 2024. PMID: 39237634 Free PMC article. Clinical Trial.

3

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.

Takahashi S, Uemura M, Kimura T, Kawasaki Y, Takamoto A, Yamaguchi A, Melhem-Bertrandt A, Gartner EM, Inoue T, Akazawa R, Kadokura T, Tanikawa T. Takahashi S, et al. Among authors: kadokura t. Invest New Drugs. 2020 Aug;38(4):1056-1066. doi: 10.1007/s10637-019-00844-x. Epub 2019 Aug 14. Invest New Drugs. 2020. PMID: 31444589 Free PMC article. Clinical Trial.

4

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.

James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. James AJ, et al. Among authors: kadokura t. Clin Pharmacokinet. 2020 Oct;59(10):1273-1290. doi: 10.1007/s40262-020-00888-w. Clin Pharmacokinet. 2020. PMID: 32304015 Free PMC article. Clinical Trial.

5

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects.

Kadokura T, Oikawa K, Miyata K, Murase T, Nakamura M. Kadokura T, et al. Clin Pharmacol Drug Dev. 2013 Oct;2(4):328-35. doi: 10.1002/cpdd.50. Epub 2013 Aug 16. Clin Pharmacol Drug Dev. 2013. PMID: 27121937

6

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.

Saito M, Kaibara A, Kadokura T, Toyoshima J, Yoshida S, Kazuta K, Ueyama E. Saito M, et al. Among authors: kadokura t. Diabetes Ther. 2020 Apr;11(4):951-964. doi: 10.1007/s13300-020-00785-2. Epub 2020 Mar 12. Diabetes Ther. 2020. PMID: 32166619 Free PMC article.

7

The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.

Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, Eltink C, Onkels H. Groenendaal D, et al. Among authors: kadokura t. Clin Pharmacol Drug Dev. 2014 May;3(3):194-201. doi: 10.1002/cpdd.93. Epub 2014 Mar 3. Clin Pharmacol Drug Dev. 2014. PMID: 27128609 Clinical Trial.

8

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.

Zhang W, Krauwinkel WJ, Keirns J, Townsend RW, Lasseter KC, Plumb L, Kadokura T, Ushigome F, Smulders R. Zhang W, et al. Among authors: kadokura t. Clin Drug Investig. 2013 Jul;33(7):489-96. doi: 10.1007/s40261-013-0089-6. Clin Drug Investig. 2013. PMID: 23733389

9

Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.

Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Veltkamp SA, et al. Among authors: kadokura t. Clin Ther. 2012 Aug;34(8):1761-71. doi: 10.1016/j.clinthera.2012.06.027. Epub 2012 Jul 15. Clin Ther. 2012. PMID: 22795925 Clinical Trial.

10

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.

Zhang W, Smulders R, Abeyratne A, Dietz A, Krauwinkel W, Kadokura T, Keirns J. Zhang W, et al. Among authors: kadokura t. Clin Ther. 2013 Aug;35(8):1150-1161.e3. doi: 10.1016/j.clinthera.2013.06.009. Epub 2013 Aug 2. Clin Ther. 2013. PMID: 23910665 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters